Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Status:
Terminated
Trial end date:
2020-03-02
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors.
The study has three separate treatment groups where separate epigenetic agents are evaluated
with an immunotherapy combination. Treatment Group A will evaluate the DNA methyltransferase
inhibitor azacitidine in combination with the programmed death receptor-1 (PD-1) inhibitor
pembrolizumab and the indoleamine 2,3-dioxygenase (IDO-1) inhibitor epacadostat; Treatment
Group B will evaluate the bromodomain and extra-terminal (BET) inhibitor INCB057643 with
pembrolizumab and epacadostat; and Treatment Group C will evaluate the lysine-specific
demethylase 1A (LSD1) inhibitor INCB059872 with pembrolizumab and epacadostat. The study will
be divided into 2 parts (Part 1 and 2). Part 1 is a dose-escalation assessment to evaluate
the safety and tolerability of the combination therapies. Once the recommended doses have
been determined, subjects with previously treated NSCLC, microsatellite-stable colorectal
cancer (CRC), head and neck squamous cell carcinoma, urothelial carcinoma, and melanoma will
be enrolled into expansion cohorts in Part 2.